- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05221359
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes (Pilot'Ex)
An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes With High Glucose Fluctuations, Prone to Severe Hypoglycemia
연구 개요
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Strasbourg, 프랑스, 67000
- 모병
- Hôpitaux Universitaires de Strasbourg
-
연락하다:
- Nathalie Jeandidier, MD
- 전화번호: +33 3 88 11 66 03
- 이메일: Nathalie.jeandidier@chru-strasbourg.fr
-
수석 연구원:
- Nathalie Jeandidier, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Adult men or women (age ≥ 18 years);
- Diagnosis of Type 1 Diabetes (T1D) for more than 2 years at the start of screening;
- Body mass index (BMI) > 16 kg/m2 and < 35 kg/m2;
Well managed intensive SubCutaneous (SC) insulin therapy, i.e. patient using for at least 3 months:
- CSII, whatever the insulin pump used, and
- Continuous Glucose Monitoring (CGM), by using Dexcom G6;
- 7.0% < Serum HbA1c < 12.0%;
Patient characterized by one of the following conditions:
Unstable diabetes/poor glycemic control, meaning patient presenting:
- at least one episode of severe hypoglycemia during the 12 months prior to study screening. Severe hypoglycemia is defined by American Diabetes Association (ADA) standards as "severe cognitive impairment requiring assistance from another person for recovery" (as per ADA's definition in "standards of care in diabetes");
- or glycemic excursions (post-prandial hyperglycemic or nocturnal hypoglycemic episodes) considered as too frequent and of high amplitude by the investigator, during the previous month;
Presence of adverse side effects of SC insulin-therapy:
- SC insulin resistance;
- or severe acquired lipodystrophy resistant to pump treatment;
- or genetic skin atrophy or lipodystrophy.
Exclusion Criteria:
- Renal glomerular filtration rate <30 mL/min/1.73m2 as per Chronic Kidney Disease - Epidemiology Collaboration (CDK-EPI) calculation;
- Immunocompromised patient;
- Local or systemic acute or chronic inflammation (rheumatoid arthritis, sclerodermia);
- Active infection or inflammation;
- Known history of skin affliction that could impact ExOlin® tolerance;
- Ongoing active anticoagulant therapy;
- Severe wound healing issues;
- Parietal reinforcement prostheses;
- Known allergy to one of the devices' components, including known allergy to fixation systems (e.g. patch, plaster) for SC administration devices such as external pumps and CGM, or chronic allergy related to prolonged wearing of such systems;
- Known allergy to insulin NovoRapid®;
- Known allergy to anesthetics, or products containing iodine and its derivates, or antibiotics used during surgery (cefazolin, and combination of clindamycin and gentamycin);
- Activity contraindicated as per external pump and CGM use recommendations;
- Patient willing to practice activities with risks of trauma or major change in the environment pressure such as combat sport or scuba diving;
- Cardiac condition incompatible with surgery requirements as per anesthesiologist's opinion;
- Unstable diabetic retinopathy (as per ophthalmologist's review within 6 months before screening);
- Current or history of unresolved malignancy within 5 years before screening (with exceptions for squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast carcinoma without lymph node metastases, well-differentiated thyroid carcinoma or other non-invasive lesion that, in the opinion of the investigator, is considered as cured with minimal risk of recurrence within 5 years);
- Other surgical or medical condition that, in the judgment of the investigator, might warrant exclusion or be contraindicated, like for instance visual or hand-use symptoms;
- Mental handicap or psychiatric condition incompatible with appropriate handling of devices or compliance to treatment or investigation-related tasks;
- Known active alcohol or drug abuse;
- Having received corticoid treatment within 4 weeks prior to enrollment;
- Having received an investigational product within 12 weeks prior to enrollment, or currently participating in another clinical trial, with the exception of observational / non-interventional; registries, for which written prior approval of Defymed is needed;
- Women planning for pregnancy, being pregnant or breastfeeding or unwilling to use adequate contraceptive methods for the duration of the study (oral hormonal contraceptives, implants, injectables, hormonal or copper intrauterine device, or vasectomized partner);
- Person under guardianship, trusteeship or deprived of liberty;
- Person not affiliated to one of the French social security systems;
- Unwilling to give written informed consent to participation in the study, or unable to do so for psychiatric, cognitive or linguistic reasons.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: test arm
All patients will be enrolled in same arm which contains the two interventions (device + drug) and follow mandatory phases of trial: screening, implantation, treatment with ExOlin, explantation.
|
Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin. Device explanted with a safety follow-up.
Use of NovoRapid insulin during all periods of the clinical investigations
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Safety: Percentage of patients who will experience at least one relevant adverse event (AE) judged by the investigator as probably or highly probably related to ExOlin® for the duration of mandatory phases of the study
기간: From implantation of the device (4 weeks after screening visit) till end of post-explantation safety follow-up (week 36), meaning a duration of 32 weeks.
|
Percentage of patients who will experience at least one relevant adverse event (AE) judged by the investigator as probably or highly probably related to ExOlin® for the duration of the study :
The primary endpoint will be achieved when the device has been retrieved from all enrolled patients and post-explantation observation time (3 months post explantation) has been completed. |
From implantation of the device (4 weeks after screening visit) till end of post-explantation safety follow-up (week 36), meaning a duration of 32 weeks.
|
Safety: Percentage of patients who will experience at least one relevant adverse event (AE) judged by the investigator as probably or highly probably related to ExOlin® for the whole duration of the study (extension phase included)
기간: From implantation of the device (4 weeks after screening visit) till end of post-explantation safety follow-up, meaning a duration up to of 168 weeks maximum for patients completing extension phase.
|
Percentage of patients who will experience at least one relevant adverse event (AE) judged by the investigator as probably or highly probably related to ExOlin® for the duration of the study :
The primary endpoint will be achieved when the device has been retrieved from all enrolled patients and post-explantation observation time (3 months post explantation) has been completed. |
From implantation of the device (4 weeks after screening visit) till end of post-explantation safety follow-up, meaning a duration up to of 168 weeks maximum for patients completing extension phase.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Safety : Percentage of patients who will experience at least one AE, according to its severity, seriousness, relation with the device or the surgery or the treatment, outcome, by system-organ-class and preferred term.
기간: From implantation of the device through study completion, meaning from 1 month after screening, duration of 8 months for mandatory phases and up to 3 years and 3 months for patients reaching end of extension phase
|
Percentage of patients who will experience at least one AE, according to its severity, seriousness, relation with the device or the surgery or the treatment, outcome, by system-organ-class and preferred term.
|
From implantation of the device through study completion, meaning from 1 month after screening, duration of 8 months for mandatory phases and up to 3 years and 3 months for patients reaching end of extension phase
|
Safety: Percentage of participants with abnormal vital signs or physical findings.
기간: From implantation of the device through study completion, meaning from 1 month after screening, duration of 8 months for mandatory phases and up to 3 years and 3 months for patients reaching end of extension phase
|
Percentage of participants with abnormal vital signs (blood pressures, heart rate, body temperature) or physical findings (i.e.
significant abnormal lab results s.a.
WBC or observation of abnormal scar)
|
From implantation of the device through study completion, meaning from 1 month after screening, duration of 8 months for mandatory phases and up to 3 years and 3 months for patients reaching end of extension phase
|
Early Performance: Glycemic control
기간: 2nd month of treatment (meaning week 20) vs end of screening (week 4)
|
Glycemic control as measured by use of a Continuous Glucose Monitor (Dexcom G6): comparison of data collected when ExOlin® is used versus data collected during Continuous Subcutaneous Insulin Infusion (CSII)
|
2nd month of treatment (meaning week 20) vs end of screening (week 4)
|
Early Performance: Glycemic control
기간: 3rd month of treatment (meaning week 24) vs end of screening (week 4)
|
Glycemic control as measured by use of a Continuous Glucose Monitor (Dexcom G6): comparison of data collected when ExOlin® is used versus data collected during Continuous Subcutaneous Insulin Infusion (CSII)
|
3rd month of treatment (meaning week 24) vs end of screening (week 4)
|
Early Performance: Glycemic control
기간: Every 4 weeks starting from 2nd month of treatment (meaning week 20) and till end of use of ExOlin (up to week 160) vs end of screening (week 4)
|
Glycemic control during the global Follow-Up (FU) of the patient across all study (monthly values, by use of Continuous Glucose Monitor Dexcom G6) by comparison of data collected when ExOlin® is used versus data collected during CSII
|
Every 4 weeks starting from 2nd month of treatment (meaning week 20) and till end of use of ExOlin (up to week 160) vs end of screening (week 4)
|
Early Performance
기간: Baseline, then every 12 weeks up to end of use of ExOlin (up to week 160)
|
Glycemic control as per HbA1c
|
Baseline, then every 12 weeks up to end of use of ExOlin (up to week 160)
|
Quality of Life: Overall score and subscores of the Diabetes Quality of Life (DQOL) questionnaire
기간: at the end of the Treatment phase (3rd month of treatment) versus data at the end of the Screening phase (1 month duration)
|
Overall score and subscores of the Diabetes Quality of Life (DQOL) questionnaire: scale from 0 to 100.
The higher patient rates, the better the outcome is.
|
at the end of the Treatment phase (3rd month of treatment) versus data at the end of the Screening phase (1 month duration)
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- DEXN-T1D-2017-01
- 2020-A01763-36 (레지스트리 식별자: ID-RCB France)
- 2020-003020-17 (EudraCT 번호)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
제1형 당뇨병에 대한 임상 시험
-
Rhythm Pharmaceuticals, Inc.완전한Pro-opiomelanocortin(POMC), Proprotein Convertase Subtilisin/Kexin Type 1(PCSK1) 및 Leptin 수용체(LepR) 유전자 돌연변이미국, 이스라엘, 캐나다, 독일, 그리스, 이탈리아, 포르투갈
-
Chong Kun Dang Pharmaceutical완전한
-
Sohag Universitysohag university hospital모병
-
Centre hospitalier de l'Université de Montréal...Maisonneuve-Rosemont Hospital모병Boston Keratoprosthesis Type I의 각막 용해캐나다
-
Xiang XieXinjiang Medical University아직 모집하지 않음암 | 죽상동맥경화성 심혈관 질환 | ASCVD | Proprotein Convertase Subtilisin/Kexin Type 9 억제제
-
University of Bologna완전한
-
Oxford Brookes UniversityUniversity of Oxford완전한신체 활동 | 정신 건강 웰니스 1 | 인지 기능 1, 사회적 | Academic Attainment | Fitness Testing영국
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National... 그리고 다른 협력자들완전한
-
Tianjin Chest Hospital모병급성관상동맥증후군 | Proprotein Convertase Subtilisin/Kexin Type 9 억제제중국
-
Postgraduate Institute of Medical Education and...완전한
ExOlin®에 대한 임상 시험
-
Novartis Pharmaceuticals완전한
-
Guerbet완전한원발성 뇌종양콜롬비아, 대한민국, 미국, 멕시코
-
Chung-Ang University Hosptial, Chung-Ang University...알려지지 않은